These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 29299820)

  • 1. Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma).
    Lenders N; McCormack A
    Pituitary; 2018 Apr; 21(2):217-229. PubMed ID: 29299820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.
    Annamalai AK; Dean AF; Kandasamy N; Kovacs K; Burton H; Halsall DJ; Shaw AS; Antoun NM; Cheow HK; Kirollos RW; Pickard JD; Simpson HL; Jefferies SJ; Burnet NG; Gurnell M
    Pituitary; 2012 Sep; 15(3):276-87. PubMed ID: 22076588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory nonfunctioning pituitary adenomas.
    Kolitz T; Greenman Y
    Pituitary; 2023 Jun; 26(3):278-280. PubMed ID: 36786972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
    Nf L; Ai M
    Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
    Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
    J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas.
    Lee JC; Pekmezci M; Lavezo JL; Vogel H; Katznelson L; Fraenkel M; Harsh G; Dulai M; Perry A; Tihan T
    Endocr Pathol; 2017 Dec; 28(4):287-292. PubMed ID: 28994039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.
    Raverot G; Castinetti F; Jouanneau E; Morange I; Figarella-Branger D; Dufour H; Trouillas J; Brue T
    Clin Endocrinol (Oxf); 2012 Jun; 76(6):769-75. PubMed ID: 22404748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How effective is temozolomide for treating pituitary tumours and when should it be used?
    Halevy C; Whitelaw BC
    Pituitary; 2017 Apr; 20(2):261-266. PubMed ID: 27581836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
    Lamas C; Cámara R; Fajardo C; Remon-Ruiz P; Biagetti B; Guerrero-Pérez F; Araujo-Castro M; Mora M; Hanzu F; Iglesias P; García-Centeno R; Soto A
    Front Endocrinol (Lausanne); 2023; 14():1204206. PubMed ID: 37720528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary tumours - a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre.
    Rak B; Maksymowicz M; Grzywa TM; Sajjad E; Pękul M; Włodarski P; Zieliński G
    Endokrynol Pol; 2020; 71(2):116-125. PubMed ID: 32154573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary tumour types in dogs and cats.
    Sanders K; Galac S; Meij BP
    Vet J; 2021 Apr; 270():105623. PubMed ID: 33641809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
    Hirohata T; Ishii Y; Matsuno A
    Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
    Hagen C; Schroeder HD; Hansen S; Hagen C; Andersen M
    Eur J Endocrinol; 2009 Oct; 161(4):631-7. PubMed ID: 19654234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rab3B immunoexpression in human pituitary adenomas.
    Rotondo F; Scheithauer BW; Kovacs K; Bell DC
    Appl Immunohistochem Mol Morphol; 2009 May; 17(3):185-8. PubMed ID: 19384079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
    Raverot G; Jouanneau E; Trouillas J
    Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Accurate Subtyping of Pituitary Adenomas: Perspectives from the Treating Physician.
    Gomez-Hernandez K; Ezzat S; Asa SL; Mete Ö
    Turk Patoloji Derg; 2015; 31 Suppl 1():4-17. PubMed ID: 26177314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
    Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive pituitary adenomas--diagnosis and emerging treatments.
    Di Ieva A; Rotondo F; Syro LV; Cusimano MD; Kovacs K
    Nat Rev Endocrinol; 2014 Jul; 10(7):423-35. PubMed ID: 24821329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience.
    Erickson D; Scheithauer B; Atkinson J; Horvath E; Kovacs K; Lloyd RV; Young WF
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):92-9. PubMed ID: 19170710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.